| General Information | |
|---|---|
| ZINC ID | ZINC000072113381 |
| Molecular Weight (Da) | 545 |
| SMILES | CC(C)(NC(=O)c1cn(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2)n1)c1nnc(C(F)(F)F)o1 |
| Molecular Formula | C22Cl3F3N5O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 124.408 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 35 |
| LogP | 6.168 |
| Activity (Ki) in nM | 12.8825 |
| Polar Surface Area (PSA) | 85.84 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.894 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.18 |
| Ilogp | 4.35 |
| Xlogp3 | 5.7 |
| Wlogp | 7.61 |
| Mlogp | 4 |
| Silicos-it log p | 5.76 |
| Consensus log p | 5.48 |
| Esol log s | -6.81 |
| Esol solubility (mg/ml) | 0.0000841 |
| Esol solubility (mol/l) | 0.00000015 |
| Esol class | Poorly sol |
| Ali log s | -7.27 |
| Ali solubility (mg/ml) | 0.0000293 |
| Ali solubility (mol/l) | 5.39E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.76 |
| Silicos-it solubility (mg/ml) | 9.53E-08 |
| Silicos-it solubility (mol/l) | 1.75E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.58 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.48 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.318 |
| Logd | 4.199 |
| Logp | 5.273 |
| F (20%) | 0 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 99.96% |
| Vdss | 3.226 |
| Fu | 0.82% |
| Cyp1a2-inh | 0.254 |
| Cyp1a2-sub | 0.912 |
| Cyp2c19-inh | 0.765 |
| Cyp2c19-sub | 0.06 |
| Cl | 2.249 |
| T12 | 0.033 |
| H-ht | 0.563 |
| Dili | 0.986 |
| Roa | 0.286 |
| Fdamdd | 0.929 |
| Skinsen | 0.068 |
| Ec | 0.003 |
| Ei | 0.006 |
| Respiratory | 0.927 |
| Bcf | 1.984 |
| Igc50 | 4.264 |
| Lc50 | 5.239 |
| Lc50dm | 5.457 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.1 |
| Nr-aromatase | 0.944 |
| Nr-er | 0.458 |
| Nr-er-lbd | 0.046 |
| Nr-ppar-gamma | 0.404 |
| Sr-are | 0.918 |
| Sr-atad5 | 0.046 |
| Sr-hse | 0.177 |
| Sr-mmp | 0.81 |
| Sr-p53 | 0.886 |
| Vol | 462.241 |
| Dense | 1.175 |
| Flex | 0.304 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.307 |
| Synth | 3.026 |
| Fsp3 | 0.182 |
| Mce-18 | 29 |
| Natural product-likeness | -1.212 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |